Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The firm said they delivered a top- and bottom-line beat for 4Q24 driven by continued growth and demand in the Crysvita, Dojolvi, and Evkeeza franchises.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- 3 Best Stocks to Buy Now, 2/18/2025, According to Top Analysts
- Ultragenyx Pharmaceutical: Strong Growth Prospects and Pipeline Advancements Reinforce Buy Rating
- Ultragenyx Reports Strong Growth Amid Challenges
- Ultragenyx price target raised to $86 from $73 at TD Cowen
- Ultragenyx Pharmaceutical: Promising Growth Prospects with Strong Financial Outlook and Key Pipeline Developments